|Bid||63.25 x 1400|
|Ask||70.70 x 800|
|Day's range||63.76 - 65.67|
|52-week range||59.55 - 90.19|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||N/A|
|Earnings date||03-Aug-2021 - 09-Aug-2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||97.53|
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE).
Arena announces first participant randomized in Phase 2 trial evaluating IV temanogrel for the potential treatment of cMVO in patients undergoing PCI.
Arena Pharmaceuticals today announced that as of 2021, Arena received an MSCI ESG Rating of "A."